Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
13d
Travere Therapeutics: Strong Growth and Strategic Advancements Drive Buy Rating
Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...
16d
Buy Rating Affirmed for Travere Therapeutics Amid Promising Filspari Efficacy in Treating IgAN and FSGS
Canaccord Genuity analyst Edward Nash has maintained their bullish stance on TVTX stock, giving a Buy rating yesterday. Edward Nash has given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Tapped for health secretary
Florida sues FEMA officials
Vonn ending her retirement
Named grand marshal
FBI offering up to $25K
E. coli cases climb to 104
Largest coral ever recorded
FBI raids Coplan's home
To close hundreds of stores
Faces up to $165M penalty
Bohannan requests recount
To replace Kotb on 'Today'
Remains ID'd after 82 years
DOJ report on Fulton jail
House GOP conference chair
Notre Dame set to reopen
China hacked telecom firms
Briefly detained at airport
Seeks pause in docs appeal
Israeli airstrikes hit Syria
The Onion buys Infowars
Ban on executives upheld
Judge blocks name change
Global increase in diabetes
Israel accused of war crimes
EU fines Meta
Teen guilty of swatting calls
Weekly jobless claims fall
Gaetz resigns from Congress
Feedback